Early Onset of Autoimmune Disease by the Retroviral Integrase Inhibitor Raltegravir

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.0908074106
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Evidence That Raltegravir (Isentress, Merck), a Retroviral Integrase Inhibitor Is Effective Against Recurrent Human Herpes Simplex Virus Infection Associated With NK-cell Deficiency

Pediatrics & Therapeutics
2013English

Mutations Associated With Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor in Vitro

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2008English

Raltegravir: A Potent and Safe Integrase Inhibitor With a Favourable Impact on Cardiovascular and Liver Profile

Journal of the International AIDS Society
EnvironmentalPublic HealthInfectious DiseasesOccupational Health
2008English

A Long-Acting Formulation of the Integrase Inhibitor Raltegravir Protects Humanized BLT Mice From Repeated High-Dose Vaginal HIV Challenges

Journal of Antimicrobial Chemotherapy
Infectious DiseasesMicrobiologyPharmacology
2016English

Retroviral Integrase Structure and DNA Recombination Mechanism

2015English

Early-Onset Alzheimer Disease

Neurologic Clinics
Neurology
2017English

Early Onset Alzheimer's Disease

MOJ Gerontology & Geriatrics
2018English

Early-Onset Lafora Body Disease

2020English

Figure 1: FDA Approved Integrase Strand Transfer Inhibitors INSTIs: Raltegravir, Elvitegravir and Dolutegravir.

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy